Notable Wednesday Option Activity: ASTS, STZ, AMGN

Options activity in Constellation Brands (STZ) and Amgen (AMGN) showed unusually high volume: STZ saw 21,462 contracts (≈2.1M underlying shares), about 81.5% of its one‑month average daily share volume, led by 1,417 contracts in the $142 call expiring Jan 9, 2026 (≈141,700 shares). AMGN recorded 22,670 contracts (≈2.3M underlying shares), ~80.2% of its one‑month average, driven by 10,087 contracts in the $365 call expiring Feb 20, 2026 (≈1.0M shares). The concentration in large call strikes indicates significant speculative/positioning flows that could affect near‑term options-implied volatility and equity order flow for the two names.

Analysis

Market structure: The concentrated call volume in AMGN (≈1.0M underlying shares at $365 Feb‑20‑2026) and STZ (≈142.7k at $142 Jan‑09‑2026) equals ~80% of each name's ADV, implying dealer delta-hedging will likely bid the underlying into expiries. Short‑gamma exposure on desks creates asymmetric upside pressure in the next 1–12 weeks; beneficiaries are long equity holders and short sellers forced to cover, while liquidity providers and option sellers absorb elevated hedging costs.

Risk assessment: Tail risks differ by ticker — AMGN carries biotech/regulatory/cliff event risk (trial/FDA cadence over next 12–18 months) while STZ faces consumer demand/tax/regulatory shifts in beverage markets. Immediate (days) risk is gamma‑pinch and short squeezes; short‑term (weeks–months) is IV repricing and position roll; long‑term (quarters–years) fundamentals reassert (earnings, R&D outcomes). Hidden dependency: large volumes can be spreads or covered writes; verify tradeprints and block sizes to avoid mistaking roll/hedge flow for directional conviction.

Trade implications: Favor asymmetric option structures sized small (1–2% portfolio) to capture dealer‑driven theta: for AMGN use Feb‑2026 call spreads around 365 (buy 365/415) to limit bleed if IV compresses; for STZ use Jan‑2026 142/152 call spreads or a 1% outright equity buy with a 6–8% stop. Consider a relative‑value long AMGN vs short JNJ (dollar‑neutral 1% position) to isolate idiosyncratic upside into Feb 2026 expiries.

Contrarian angle: High call volume is not definitive bullishness — it can be sell‑writes, structured product hedges, or liquidity trades that unwind post‑expiry, producing mean reversion. If IV spikes >25% from baseline or open interest concentration persists >60 days without fundamental catalysts (earnings/FDA/M&A), expect a violent unwind; position sizes should assume a 30–60% drawdown on option premiums before fundamentals confirm direction.

Key Decisions for Investors

• Establish a 1–2% portfolio notional long via AMGN Feb‑20‑2026 365/415 call spreads (buy 365, sell 415) to capture upside while limiting premium loss; scale into trade over two sessions and trim 50% if AMGN rallies >5% vs entry or if IV rises >20% from entry.
• Take a 1% long position in STZ via Jan‑09‑2026 142/152 call spread (buy 142, sell 152) or 1% outright equity if spreads unavailable; set a tactical stop of 8% on the stock leg or a 60% loss limit on option premium, and close if open interest concentration falls below 30% of ADV.
• Initiate a dollar‑neutral relative trade: long AMGN and short JNJ sized to equal beta (target net market exposure ≈0), 1% portfolio notional each, to exploit idiosyncratic AMGN upside into Feb‑2026; unwind within 90 days or if the pair diverges by >7%.